CTXR Overview

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Wall Street analysts forecast CTXR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Citius Pharmaceuticals Inc revenue for the last quarter amounts to 3.94M USD, decreased

Citius Pharmaceuticals Inc. EPS for the last quarter amounts to -0.38 USD, decreased -70.77

Citius Pharmaceuticals Inc (CTXR) has 23 emplpoyees as of March 21 2026.

Today CTXR has the market capitalization of 17.24M USD.